Iadademstat (ORY-1001)
Acute Myeloid Leukemia (AML)
Key Facts
About Oryzon Genomics
Oryzon Genomics leverages its proprietary epigenetic platform to discover and develop personalized therapeutics for oncology and CNS diseases. As a publicly traded company, it has advanced its lead LSD1 inhibitor, iadademstat, into multiple Phase II trials, including for acute myeloid leukemia (AML) and essential thrombocythemia, while also expanding its patent portfolio globally. The company's strategy focuses on biomarker-driven development and combination therapies, particularly with immuno-oncology agents, to address significant unmet medical needs.
View full company profileAbout Oryzon Genomics
Oryzon Genomics leverages its proprietary epigenetic platform to discover and develop personalized therapeutics for oncology and CNS diseases. As a publicly traded company, it has advanced its lead LSD1 inhibitor, iadademstat, into multiple Phase II trials, including for acute myeloid leukemia (AML) and essential thrombocythemia, while also expanding its patent portfolio globally. The company's strategy focuses on biomarker-driven development and combination therapies, particularly with immuno-oncology agents, to address significant unmet medical needs.
View full company profileAbout Oryzon Genomics
Oryzon Genomics leverages its proprietary epigenetic platform to discover and develop personalized therapeutics for oncology and CNS diseases. As a publicly traded company, it has advanced its lead LSD1 inhibitor, iadademstat, into multiple Phase II trials, including for acute myeloid leukemia (AML) and essential thrombocythemia, while also expanding its patent portfolio globally. The company's strategy focuses on biomarker-driven development and combination therapies, particularly with immuno-oncology agents, to address significant unmet medical needs.
View full company profileTherapeutic Areas
Other Acute Myeloid Leukemia (AML) Drugs
| Drug | Company | Phase |
|---|---|---|
| NTLA-5001 | Intellia Therapeutics | Phase 1/2 |
| Galinpepimut-S (GPS) | SELLAS Life Sciences | Phase 2/3 |
| SLS009 (GFH009) | SELLAS Life Sciences | Phase 1/2 |
| UCART123 | Cellectis | Phase 1 |
| MP0533 | Molecular Partners | Phase 1/2 |
| SEL24 (MEN1703) | Selvita | Phase 1/2 |
| Selinexor | Karyopharm Therapeutics | Clinical Trials |
| NEX-20 (azacitidine) | Nanexa AB | Phase 1 |
| SENTI-202 | Senti Biosciences | Phase 1 |
| motixafortide (BL-8040) | BioLineRx | Phase 2a |
| ACD-101 | Advanced Cellular Dynamics | Phase 1 |
| ABD-3001 | Advanced Biodesign | Phase 1 |